Literature DB >> 17366247

Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore.

Richard D Semba1, Erin P Ricketts, Shruti F Mehta, Gregory D Kirk, Carl Latkin, Noya Galai, David Vlahov.   

Abstract

Adherence and retention of female injection drug users (IDUs) in clinical trials are not well known and were evaluated among 458 female IDUs in a clinical trial in Baltimore. Of all, 62.9% were adherent to visits (attended > or = 80% of visits). Of women with > or = 1 visit after enrollment, 76% were adherent to treatment (took > or = 80% of pills); 27.7% were lost to follow-up (missed > or = 3 consecutive visits). Women nonadherent to visits were younger and less likely to be on methadone. Women lost to follow-up were younger, more often white, not on methadone, and injecting drugs daily. Fair-moderate adherence to visits and treatment occurs among female IDUs in a clinical trial.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17366247     DOI: 10.1080/00952990601082696

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  7 in total

Review 1.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

2.  Retention in the National Institute on Drug Abuse Clinical Trials Network Women and Trauma Study: implications for posttrial implementation.

Authors:  Rogério M Pinto; Aimee N C Campbell; Denise A Hien; Gary Yu; Prakash Gorroochurn
Journal:  Am J Orthopsychiatry       Date:  2011-04

Review 3.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

4.  Retention and attendance of women enrolled in a large prospective study of HIV-1 in the United States.

Authors:  Nancy A Hessol; Kathleen M Weber; Susan Holman; Esther Robison; Lakshmi Goparaju; Christine B Alden; Naoko Kono; D Heather Watts; Niloufar Ameli
Journal:  J Womens Health (Larchmt)       Date:  2009-10       Impact factor: 2.681

5.  Retention in care within 1 year of initial HIV care visit in a multisite US cohort: who's in and who's out?

Authors:  Ellen M Tedaldi; James T Richardson; Rachel Debes; Benjamin Young; Joan S Chmiel; Marcus D Durham; John T Brooks; Kate Buchacz
Journal:  J Int Assoc Provid AIDS Care       Date:  2014-02-03

6.  Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial.

Authors:  Andreas Maieron; Sigrid Metz-Gercek; Thomas-Matthias Scherzer; Hermann Laferl; Gabriele Fischer; Martin Bischof; Michael Gschwantler; Peter Ferenci
Journal:  BMC Res Notes       Date:  2011-06-29

7.  Inclusion of special populations in clinical research: important considerations and guidelines.

Authors:  Stuart S Winter; Janet M Page-Reeves; Kimberly A Page; Emily Haozous; Angelica Solares; Carla Nicole Cordova; Richard S Larson
Journal:  J Clin Transl Res       Date:  2018-04-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.